Skip to main content
Top
Published in: Journal of Clinical Immunology 5/2008

01-09-2008

Genetic Polymorphisms in the CD40 Ligand Gene and Kawasaki Disease

Authors: Fu-Yuan Huang, Tzu-Yang Chang, Ming-Ren Chen, Nan-Chang Chiu, Hsin Chi, Hung-Chang Lee, Shuan-Pei Lin, Chih-Kai Chen, Hui-Wen Chan, Wei-Fang Chen, Hsin-Fu Liu, Chen-Chung Chu, Marie Lin, Yann-Jinn Lee

Published in: Journal of Clinical Immunology | Issue 5/2008

Login to get access

Abstract

Background

Although some previous studies have reported that genetic and immunological factors play important roles in the pathogenesis of Kawasaki disease (KD), the etiological factors of this enigmatical pediatric disease are still poorly understood.

Purpose

This study aims to investigate whether polymorphisms of the CD40 ligand (CD40L) gene are associated with KD and the development of coronary artery lesions (CAL) in the Taiwanese children.

Materials and methods

The CD40L −3459 A/G and IVS4+121 A/G single nucleotide polymorphisms (SNPs) were genotyped in 167 children with KD and 1,010 ethnically matched healthy controls by TaqMan assay.

Results

None of the CD40L polymorphisms was associated with susceptibility or CAL development of KD, and this finding was supported by the haplotype analysis.

Conclusion

In summary, these results provide little support for specific CD40L SNPs in the susceptibility or CAL development of KD in Taiwanese children. However, it will be necessary to validate or replicate this association in other independent large-size ethnic groups.
Literature
1.
go back to reference Laupland KB, Dele Davies H. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr Cardiol 1999;20:177–83.PubMedCrossRef Laupland KB, Dele Davies H. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr Cardiol 1999;20:177–83.PubMedCrossRef
2.
go back to reference Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–6.PubMed Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–6.PubMed
3.
go back to reference Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776–80.PubMed Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776–80.PubMed
4.
go back to reference Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991;119:279–82.PubMedCrossRef Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991;119:279–82.PubMedCrossRef
5.
go back to reference Yanagawa H, Nakamura Y, Yashiro M, Fujita Y, Nagai M, Kawasaki T, et al. A nationwide incidence survey of Kawasaki disease in 1985–1986 in Japan. J Infect Dis 1988;158:1296–301.PubMed Yanagawa H, Nakamura Y, Yashiro M, Fujita Y, Nagai M, Kawasaki T, et al. A nationwide incidence survey of Kawasaki disease in 1985–1986 in Japan. J Infect Dis 1988;158:1296–301.PubMed
6.
go back to reference Morens DM, Anderson LJ, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics 1980;65:21–5.PubMed Morens DM, Anderson LJ, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics 1980;65:21–5.PubMed
7.
8.
go back to reference van Kooten C, Banchereau J. CD40–CD40 ligand. J Leukoc Biol 2000;67:2–17.PubMed van Kooten C, Banchereau J. CD40–CD40 ligand. J Leukoc Biol 2000;67:2–17.PubMed
9.
go back to reference Grewal IS, Flavell RA. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 1996;17:410–4.PubMedCrossRef Grewal IS, Flavell RA. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 1996;17:410–4.PubMedCrossRef
10.
go back to reference Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 1996;156:8–11.PubMed Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 1996;156:8–11.PubMed
11.
go back to reference Mackey MF, Barth RJ Jr., Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998;63:418–28.PubMed Mackey MF, Barth RJ Jr., Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998;63:418–28.PubMed
12.
go back to reference Lipsky PE, Attrep JF, Grammer AC, McIlraith MJ, Nishioka Y. Analysis of CD40–CD40 ligand interactions in the regulation of human B cell function. Ann NY Acad Sci 1997;815:372–83.PubMedCrossRef Lipsky PE, Attrep JF, Grammer AC, McIlraith MJ, Nishioka Y. Analysis of CD40–CD40 ligand interactions in the regulation of human B cell function. Ann NY Acad Sci 1997;815:372–83.PubMedCrossRef
13.
go back to reference Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998;281:96–9.PubMedCrossRef Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998;281:96–9.PubMedCrossRef
14.
go back to reference Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–4.PubMedCrossRef Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–4.PubMedCrossRef
15.
go back to reference Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826–37.PubMedCrossRef Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826–37.PubMedCrossRef
16.
go back to reference Wang CR, Liu MF. Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 2003;132:371–8.PubMedCrossRef Wang CR, Liu MF. Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 2003;132:371–8.PubMedCrossRef
17.
go back to reference Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435–41.PubMedCrossRef Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435–41.PubMedCrossRef
18.
go back to reference Laman JD, de Smet BJ, Schoneveld A, van Meurs M. CD40–CD40L interactions in atherosclerosis. Immunol Today 1997;18:272–7.PubMedCrossRef Laman JD, de Smet BJ, Schoneveld A, van Meurs M. CD40–CD40L interactions in atherosclerosis. Immunol Today 1997;18:272–7.PubMedCrossRef
19.
go back to reference Wang CL, Wu YT, Liu CA, Lin MW, Lee CJ, Huang LT, et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003;111:E140–7.PubMedCrossRef Wang CL, Wu YT, Liu CA, Lin MW, Lee CJ, Huang LT, et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003;111:E140–7.PubMedCrossRef
20.
go back to reference Onouchi Y, Onoue S, Tamari M, Wakui K, Fukushima Y, Yashiro M, et al. CD40 ligand gene and Kawasaki disease. Eur J Hum Genet 2004;12:1062–8.PubMedCrossRef Onouchi Y, Onoue S, Tamari M, Wakui K, Fukushima Y, Yashiro M, et al. CD40 ligand gene and Kawasaki disease. Eur J Hum Genet 2004;12:1062–8.PubMedCrossRef
21.
go back to reference Council on Cardiovascular Disease in the Young Committee on Rheumatic Fever E, and Kawasaki Disease American Heart Association. Diagnostic guidelines for Kawasaki disease. Circulation 2001;103:335–6. Council on Cardiovascular Disease in the Young Committee on Rheumatic Fever E, and Kawasaki Disease American Heart Association. Diagnostic guidelines for Kawasaki disease. Circulation 2001;103:335–6.
22.
go back to reference Arjunan K, Daniels SR, Meyer RA, Schwartz DC, Barron H, Kaplan S. Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiographic study. J Am Coll Cardiol 1986;8:1119–24.PubMedCrossRef Arjunan K, Daniels SR, Meyer RA, Schwartz DC, Barron H, Kaplan S. Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiographic study. J Am Coll Cardiol 1986;8:1119–24.PubMedCrossRef
23.
go back to reference Lee HH, Chao HT, Ng HT, Choo KB. Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet 1996;33:371–5.PubMed Lee HH, Chao HT, Ng HT, Choo KB. Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet 1996;33:371–5.PubMed
24.
go back to reference Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the −3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 2006;26:1667–73.PubMedCrossRef Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the −3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 2006;26:1667–73.PubMedCrossRef
25.
go back to reference Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–5.PubMedCrossRef Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–5.PubMedCrossRef
26.
go back to reference Lancaster AK, Single RM, Solberg OD, Nelson MP, Thomson G. PyPop update—a software pipeline for large-scale multilocus population genomics. Tissue Antigens 2007;69(Suppl 1):192–7.PubMedCrossRef Lancaster AK, Single RM, Solberg OD, Nelson MP, Thomson G. PyPop update—a software pipeline for large-scale multilocus population genomics. Tissue Antigens 2007;69(Suppl 1):192–7.PubMedCrossRef
27.
go back to reference Lee YJ, Chen MR, Chang WC, Lo FS, Huang FY. A freely available statistical program for testing associations. MD Comput 1998;15:327–30.PubMed Lee YJ, Chen MR, Chang WC, Lo FS, Huang FY. A freely available statistical program for testing associations. MD Comput 1998;15:327–30.PubMed
28.
go back to reference Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947–55.PubMedCrossRef Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947–55.PubMedCrossRef
30.
go back to reference Van Kooten C, Banchereau J. CD40–CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996;61:1–77.PubMedCrossRef Van Kooten C, Banchereau J. CD40–CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996;61:1–77.PubMedCrossRef
31.
go back to reference Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–35.PubMedCrossRef Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–35.PubMedCrossRef
32.
go back to reference Nash MC, Shah V, Dillon MJ. Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease. Clin Exp Immunol 1995;101:13–7.PubMed Nash MC, Shah V, Dillon MJ. Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease. Clin Exp Immunol 1995;101:13–7.PubMed
33.
go back to reference Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990;56:29–36.PubMedCrossRef Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990;56:29–36.PubMedCrossRef
34.
go back to reference Shikishima Y, Saeki T, Matsuura N. Chemokines in Kawasaki disease: measurement of CCL2, CCL22 and CXCL10. Asian Pac J Allergy Immunol 2003;21:139–43.PubMed Shikishima Y, Saeki T, Matsuura N. Chemokines in Kawasaki disease: measurement of CCL2, CCL22 and CXCL10. Asian Pac J Allergy Immunol 2003;21:139–43.PubMed
35.
go back to reference Chang LY, Chang IS, Lu CY, Chiang BL, Lee CY, Chen PJ, et al. Epidemiologic features of Kawasaki disease in Taiwan, 1996–2002. Pediatrics 2004;114:e678–82.PubMedCrossRef Chang LY, Chang IS, Lu CY, Chiang BL, Lee CY, Chen PJ, et al. Epidemiologic features of Kawasaki disease in Taiwan, 1996–2002. Pediatrics 2004;114:e678–82.PubMedCrossRef
Metadata
Title
Genetic Polymorphisms in the CD40 Ligand Gene and Kawasaki Disease
Authors
Fu-Yuan Huang
Tzu-Yang Chang
Ming-Ren Chen
Nan-Chang Chiu
Hsin Chi
Hung-Chang Lee
Shuan-Pei Lin
Chih-Kai Chen
Hui-Wen Chan
Wei-Fang Chen
Hsin-Fu Liu
Chen-Chung Chu
Marie Lin
Yann-Jinn Lee
Publication date
01-09-2008
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2008
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9203-6

Other articles of this Issue 5/2008

Journal of Clinical Immunology 5/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.